



6'AU 1614 PATENT

West Trans

TECH CENTER 1600/2900 Case Docket No. MAXIM.078A

I hereby certify that this correspondence and all

marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner

August 9, 2001

Date)

James J. Mullen/III, Ph.D., Reg. No. 44,95

for Patents, Washington, D.C. 20231, on

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Hellstrand et al.

Appl. No.

09/616,622

July 14, 2000

For

Filed

ACTIVATION AND

PROTECTION OF

CYTOTOXIC

LYMPHOCYTES USING A REACTIVE OXYGEN METABOLITE INHIBITOR

Examiner

Unknown

Group Art Unit:

1614

TRANSMITTAL LETTER

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

ATTENTION: APPLICATION BRANCH

Dear Sir:

Enclosed for filing in the above-identified application are:

- A Supplemental Information Disclosure Statement. (X)
- A Form PTO-1449 with five (5) references. (X)
- The Commissioner is hereby authorized to charge any additional fees which may be required, or (X) credit any overpayment, to Account No. 11-1410.

Return prepaid postcard. (X)

> James J/Mullen III, Ph.D. Registration No. 44,957

Attorney of Record

S:\DOCS\JJM\JJM-6456.DOC\080301





AUG 1 7 2001

PATENT

TECH CENTER 1600/2900

UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Helistrand et al.) Group Art Unit: 1614
App. No.	:	09/616,622)
Filed	:	July 14, 2000)
For	:	ACTIVATION AND PROTECTION OF CYTOTOXIC LYMPHOCYTES USING A REACTIVE OXYGEN METABOLITE INHIBITOR	RECEIVE AUG 1 7 2001 TC 1 7 00
Examiner	:	Unknown)))

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Enclosed is form PTO-1449 listing references that are also enclosed. The references disclosed were cited by the International Search Authority (ISA) in conjunction with the prosecution of the copending Patent Cooperation Treaty application.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account 11-1410.



Filed

09/616,622

July 14, 2000

CERTIFICATION UNDER 37 C.F.R.§ 1.97(e)(1)

I hereby certify that each item of information contained in this statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 9AUG-200 (

James J. Mullen III, Ph.D.

Registration No. 44,957

Attorney of Record

620 Newport Center Drive

Sixteenth Floor

Newport Beach, CA 92660

(619) 235-8550

S:\DOCS\JJM\JJM-6452.DOC 080301